Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753275 | 0.86 | ACACB (0.33) | — | |
| SCHEMBL23563318 | 0.85 | PGK1 (0.30) | — | |
| SCHEMBL22326933 | 0.85 | PGK1 (0.30) | — | |
| SCHEMBL24972510 | 0.84 | PGK1 (0.32) | — | |
| SCHEMBL24971415 | 0.83 | DDB1 (0.32) | — | |
| SCHEMBL25712577 | 0.82 | ADORA2A (0.33) | — | |
| SCHEMBL25712884 | 0.81 | HSD17B10 (0.31) | — | |
| SCHEMBL25638688 | 0.80 | — | — | |
| SCHEMBL25712880 | 0.80 | MAPKAPK2 (0.33) | — | |
| SCHEMBL14767375 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212369-A1 | NUCLEOTIDE CYCLIC CLEAVABLE MOIETIES AND USES THEREOF | Singular Genomics Systems, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-26 | — | — | US | disclosed |
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002436-A1 | MODIFIED NUCLEOTIDES AND USES THEREOF | NUDT1, RNMT, ADAR | ESR1 3411/4885KCNH2 4077/4885 |
| US-20230257414-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | ESR1 2664/4885KCNH2 3180/4885 |
| US-20230028359-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | ESR1 2664/4885KCNH2 3180/4885 |
| US-20230203083-A1 | NUCLEOTIDE ANALOGUES | ITPA, POLB, NUDT1 | ESR1 2664/4885KCNH2 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.